You are here: Industry Insights > Immutep

News List

Immutep Secures Second Patent Grant for Eftilagimod Alpha, A Pd-1 Pathway Inhibitor Combination americanpharmaceuticalreview
March 16, 2021
Immutep has announced the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office (USPTO).
Immutep Expands Part B of TACTI-002 Study americanpharmaceuticalreview
March 10, 2021
Immutep has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design. Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients ...
Ulcerative Colitis GSK2831781 Study Discontinued americanpharmaceuticalreview
January 28, 2021
Immutep Limited is advising its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative ...
Immutep Announces Australian Patent Grant for IMP701 Antibody americanpharmaceuticalreview
November 18, 2020
Immutep has announced the grant of patent no. 2015229103 entitled “Antibody molecules to LAG-3 and uses thereof” by the Australian Patent Office.
Immutep Announces IMP701 Antibody Patent americanpharmaceuticalreview
July 23, 2020
Immutep has announced the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.
Immutep Receives Second IND approval for Efti from FDA americanpharmaceuticalreview
March 10, 2020
Immutep has announced the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) for eftilagimod alpha (efti or IMP321).
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321 Wuxi Bioologics
February 24, 2020
WuXi Biologics congratulates its strategic partner Immutep on the positive interim data from the company’s ongoing Phase II TACTI-002 study.
Immutep collaborates with Merck, Pfizer for Efti biospectrum
September 26, 2018
The clinical trial will evaluate the clinical benefits of releasing the brakes and pushing the accelerator of the body’s immune system at two different positions in the cancer immunity cycle.
Immutep, Merck & Co. Enter Partnership contractpharma
March 13, 2018
Immutep Limited has entered into a clinical trial collaboration and supply agreement with Merck & Co.
Immutep Strikes Deal with Merck to Pair Product With Keytruda in Phase II Trial biospace
March 13, 2018
Australian Immutep Ltd. announced that it will use Merck’s heavy PD-1 inhibitor Keytruda to pair its primary immunotherapy product with three solid tumor types in a single trial.